<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-CTLA-4</span> <span style="margin-left: 2em;">tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">durvalumab based treatment</span> <span style="margin-left: 3em;">durvalumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">Immune checkpoint association</span> <span style="margin-left: 2em;">durvalumab plus tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2) progression or deaths (PFS) (2) objective responses (ORR) (2) DCR (2) DOR (2) TRAE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) TRAE (grade 3-4) (2) TRAE leading to death (grade 5) (2) TRAE leading to discontinuation (any grade) (2) STRAE (any grade) (1) Diarrhoea TRAE (grade 3-4) (2) Fatigue TRAE (grade 3-4) (2) Anaemia TRAE (grade 3-4) (2) Asthenia TRAE (grade 3-4) (2)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 CONDOR (DT vs D ; PDL1 TC<25%), 2019 1 CONDOR (DT vs T ; PDL1 TC<25%), 2019 durvalumab alone vs. durvalumab plus tremelimumab
1.01 [0.70; 1.45] 1.01 [0.70;1.45]durvalumab alone vs. durvalumab plus tremelimumab
1.01 [0.70; 1.45] durvalumab alone vs. tremelimumab
0.73 [0.44; 1.21] 0.73 [0.44;1.21]durvalumab alone vs. tremelimumab
0.73 [0.44; 1.21] durvalumab plus tremelimumab vs. durvalumab alone
0.99 [0.69; 1.43] 0.99 [0.69;1.43]durvalumab plus tremelimumab vs. durvalumab alone
0.99 [0.69; 1.43] durvalumab plus tremelimumab vs. tremelimumab
0.72 [0.51; 1.02] 0.72 [0.51;1.02]durvalumab plus tremelimumab vs. tremelimumab
0.72 [0.51; 1.02] tremelimumab vs. durvalumab alone
1.37 [0.83; 2.28] 1.37 [0.83;2.28]tremelimumab vs. durvalumab alone
1.37 [0.83; 2.28] tremelimumab vs. durvalumab plus tremelimumab
1.39 [0.98; 1.97] 1.39 [0.98;1.97]tremelimumab vs. durvalumab plus tremelimumab
1.39 [0.98; 1.97] durvalumab alone tremelimumab durvalumab plus tremelimumab direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C durvalumab alone tremelimumab durvalumab plus tremelimumab durvalumab alone --- 0.73 0.44; 1.211.01 0.70; 1.45tremelimumab 1.37 0.83; 2.28--- 1.39 0.98; 1.97durvalumab plus tremelimumab 0.99 0.69; 1.430.72 0.51; 1.02---
pathologies: 192
- treatments: 634,861
result logic